AB122 Platform Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zdolność do uczestniczenia w badaniu i przychodzenia na wizyty
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Prawidłowa funkcja wątroby i nerek
- •Wystarczająca liczba białych krwinek (minimum 1500/mm3)
- •Wystarczająca liczba płytek krwi (minimum 100000/mm3)
- •Hemoglobina co najmniej 9,0 g/dL
- •Spodziewana długość życia co najmniej 90 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
A site selected by Taiho Pharmaceutical Co., Ltd.
Aichi, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Chiba, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Ehime, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Hokkaido, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Kanagawa, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Osaka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Shizuoka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Tokyo, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
Wakayama, Japan
Trial contact
Drug Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.